Literature DB >> 15755503

Methylation analysis of the cell cycle control genes in myelofibrosis with myeloid metaplasia.

Takashi Kumagai1, Ayalew Tefferi, Letetia Jones, H Phillip Koeffler.   

Abstract

Promoter hypermethylation represents a primary mechanism in the inactivation of tumor suppressor genes during tumorigenesis. We analyzed the promoter methylation status of eight tumor-associated genes (p14 ARF, p15 INK4B, p16 INK4A, Rb, hMLH1, hMSH2, APC, and DAPK) in 30 patients with myelofibrosis with myeloid metaplasia (MMM) by methylation specific PCR. The study showed no hypermethylation of the promoters of p16(INK4A), Rb, hMLH1, hMSH2, APC, and DAPK genes. The p14 ARF, p15 INK4B promoters were hypermethylated in only one patient each. This study indicates that, although methylation of these genes is important in other cancers, it is rare in MMM and causation of this disease should be focused elsewhere.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15755503     DOI: 10.1016/j.leukres.2004.11.002

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  7 in total

1.  Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents.

Authors:  Xiaoli Wang; Wei Zhang; Takefumi Ishii; Selcuk Sozer; Jiapeng Wang; Mingjiang Xu; Ronald Hoffman
Journal:  Cancer Res       Date:  2009-09-14       Impact factor: 12.701

2.  Altered expression of tumor suppressor PHF20 in myeloproliferative neoplasms.

Authors:  T L Lasho; A Pardanani; A Tefferi; D I Smith
Journal:  Leukemia       Date:  2014-03-28       Impact factor: 11.528

Review 3.  Novel Therapies for Myelofibrosis.

Authors:  Kristen Pettit; Olatoyosi Odenike
Journal:  Curr Hematol Malig Rep       Date:  2017-12       Impact factor: 3.952

4.  Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells.

Authors:  Xiaoli Wang; Wei Zhang; Joseph Tripodi; Min Lu; Mingjiang Xu; Vesna Najfeld; Yan Li; Ronald Hoffman
Journal:  Blood       Date:  2010-09-21       Impact factor: 22.113

5.  Epigenetic dysregulation of secreted frizzled-related proteins in myeloproliferative neoplasms complements the JAK2V617F-mutation.

Authors:  Karla Bennemann; Oliver Galm; Stefan Wilop; Claudia Schubert; Tim H Brümmendorf; Edgar Jost
Journal:  Clin Epigenetics       Date:  2012-08-31       Impact factor: 6.551

6.  Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies.

Authors:  John Mascarenhas; Nitin Roper; Pratima Chaurasia; Ronald Hoffman
Journal:  Clin Epigenetics       Date:  2011-07-09       Impact factor: 6.551

Review 7.  Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives.

Authors:  Alessandro M Vannucchi; Paola Guglielmelli; Alessandro Rambaldi; Costanza Bogani; Tiziano Barbui
Journal:  J Cell Mol Med       Date:  2009-06-11       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.